Ionis Pharmaceuticals, Inc. (ETR:ISI)
Germany · Delayed Price · Currency is EUR | Market Cap | 6.56B -30.2% |
| Revenue (ttm) | 765.09M -7.4% |
| Net Income | -494.70M |
| EPS | -3.03 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 39.28 |
| Previous Close | 39.34 |
| Day's Range | 39.23 - 39.34 |
| 52-Week Range | 38.18 - 75.20 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Oct 28, 2026 |
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also ... [Read more]
Financial Performance
In 2025, Ionis Pharmaceuticals's revenue was $943.71 million, an increase of 33.83% compared to the previous year's $705.14 million. Losses were -$381.39 million, -15.97% less than in 2024.
Financial numbers in USD Financial StatementsNews
Ionis announces positive interim data from partner Roche's Phase 3 IMAgINATION study in IgA nephropathy (IgAN)
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and partner Roche today announced positive prespecified interim results from the ongoing Phase 3 IMAgINATION study evaluat...
Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Otsuka Pharmaceutical and Ionis Pharmaceuticals said on Tuesday their experimental drug met the main goal of a late-stage study in patients with a rare inherited form of amyotrophic lateral sclerosi...
Ionis announces Phase 3 FUSION study of ulefnersen met primary endpoint
Ionis Pharmaceuticals (IONS) and Otsuka (OTSKY) Pharmaceutical Development & Commercialization announced topline results from the Phase 3 FUSION trial evaluating ulefnersen, an investigational RNA-tar...
Otsuka Announces Transformative Phase 3 FUSION Results for Ulefnersen, Bringing the FUS-ALS Community Closer to a Potential Targeted Treatment
PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc., Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Ionis Pharmaceuticals, Inc. today announced positive...
Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Otsuka Pharmaceutical Development & Commercialization, Inc., today announced positive topline results from the Phase 3...
Ionis Pharmaceuticals price target lowered to $70 from $76 at JPMorgan
JPMorgan analyst Jessica Fye lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $70 from $76 and keeps an Overweight rating on the shares. The firm says the investment…
Cathie Wood’s ARK Investment buys 100K shares of Ionis Pharmaceuticals today
20:27 EDT Cathie Wood’s ARK Investment buys 100K shares of Ionis Pharmaceuticals (IONS) today
Ionis Pharmaceuticals Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Two breakthrough FDA approvals and a third expected soon highlight a strong year, with TRYNGOLZA's U.S. launch progressing well and targeting blockbuster sales. The pipeline advances in CNS and metabolic diseases, despite some late-stage setbacks, and next-generation programs are moving forward.
Ionis Pharmaceuticals price target lowered to $80 from $89 at Guggenheim
Guggenheim lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $80 from $89 and keeps a Buy rating on the shares. The firm’s “quick poll” of 30 U.S. cardiologists…
Ionis Pharmaceuticals Transcript: Wells Fargo 21st Annual Healthcare Conference
Multiple FDA approvals and strong launch momentum for new therapies highlight a year of strategic success. Key programs in sHTG, HAE, and HBV are advancing, while competitive positioning and pipeline innovation remain priorities.
Ionis Pharmaceuticals price target lowered to $85 from $90 at Barclays
Barclays lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $85 from $90 and keeps an Overweight rating on the shares. The firm says the Novartis-partnered pelacarsen miss creates…
Ionis Pharmaceuticals price target lowered to $84 from $87 at Raymond James
Raymond James analyst Tiago Fauth lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $84 from $87 and keeps an Outperform rating on the shares. Although the pelacarsen miss…
Ionis Pharmaceuticals price target lowered to $104 from $110 at Morgan Stanley
Morgan Stanley analyst Michael Ulz lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $104 from $110 and keeps an Overweight rating on the shares. The firm removed pelacarsen…
Ionis Pharmaceuticals price target lowered to $84 from $94 at TD Cowen
TD Cowen analyst Yaron Werber lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $84 from $94 and keeps a Buy rating on the shares. The failure of Novartis’…
Ionis Stock Sinks 10% as Analysts Cut Targets After Pelacarsen Trial Miss
Ionis Pharmaceuticals, Inc. ($IONS) shares dropped about 10% in premarket trading after a large cardiovascular trial of pelacarsen, a drug developed by Ionis and licensed to Novartis ($NVS), failed to...
Ionis Pharmaceuticals price target lowered to $54 from $61 at BMO Capital
BMO Capital lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $54 from $61 and keeps a Market Perform rating on the shares. Ionis is expected to face near-term…
Ionis Pharmaceuticals price target lowered to $85 from $95 at Canaccord
Canaccord lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $85 from $95 and keeps a Buy rating on the shares. The firm noted IONS’ partner,Novartis (NVS), announced on…
Ionis Pharmaceuticals price target lowered to $56 from $69 at Goldman Sachs
Goldman Sachs lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $56 from $69 and keeps a Neutral rating on the shares. The pelacarsen setback removes a roughly $13/share…
Ionis Pharmaceuticals price target lowered to $100 from $115 at H.C. Wainwright
H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $100 from $115 and keeps a Buy rating on the shares. The firm removed pelacarsen…
Citi sees limited immediate downside for Ionis after pelacarsen failure
After Ionis’ (IONS) partner Novartis (NVS) disclosed that the pelacarsen Phase 3 Lp(a)HORIZON study failed to meet its primary endpoint of cardiovascular risk reduction, Citi analyst Eric Joseph antic...
Ionis, Novartis' key experimental heart drug fails in late-stage trial
Ionis Pharmaceuticals and partner Novartis' experimental drug to lower high levels of a cholesterol-carrying particle in heart patients failed in a late-stage trial, the companies said on Friday.
Novartis announces Phase 3 pelacarsen study did not meet primary endpoint
Ionis Pharmaceuticals (IONS) partner Novartis (NVS) announced that the pelacarsen Phase 3 Lp(a)HORIZON study, a pioneering cardiovascular outcomes trial, did not meet its primary endpoint of reducing ...
Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner Novartis today announced that the pelacarsen Phase 3 Lp(a)HORIZON study, a pioneering cardiovascular outcomes tria...
This Biotech Wins a Big FDA Approval. Why Wall Street Is Shrugging.
Ionis Pharmaceuticals wins regulatory clearance for its quarterly injection, Zanvastro, in Alexander disease. Analysts are focused elsewhere.
Ionis Pharmaceuticals Transcript: FDA announcement
FDA approved ZANVASTRO as the first disease-modifying therapy for Alexander disease, covering both children and adults, based on strong efficacy and safety data. Launch efforts focus on rapid patient access, payer coverage, and international expansion, with peak sales expected to exceed $100 million.